The BET1L Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of SK-HEP-1 cells with targeted disruption of the BET1L gene, which encodes a Qb SNARE essential for ER-to-Golgi vesicular trafficking. This heterogeneous loss-of-function model facilitates robust analysis of BET1L-dependent transport and secretion phenotypes without the need for single-cell cloning, providing a convenient tool to study bulk cellular responses.
The parental SK-HEP-1 cell line was established from ascites fluid of a liver adenocarcinoma patient. These cells uniquely display both epithelial and endothelial markers, making them a versatile model for hepatocellular carcinoma biology, endothelial-like functions, and metastatic processes. SK-HEP-1 cells are widely used to investigate tumor cell motility, angiogenesis, and cancer-microenvironment interactions, offering a relevant background for examining the role of trafficking in cancer cell plasticity.
At the molecular level, BET1L assembles into a functional SNARE complex with SEC22B, STX5, and GOSR1 to mediate vesicle docking and fusion at the ER-Golgi intermediate compartment. This SNAREpin formation is regulated by NSF and SNAP, and governed upstream by the small GTPases ARF1 and RAB1, along with COPI coat components. Disruption of BET1L impairs anterograde transport, causing retention of cargo in the ER, reorganization of Golgi morphology, and compromised trafficking of secreted proteins, cell surface receptors, and Golgi-resident enzymes. BET1L also interacts with the related SNARE BET1, highlighting conserved roles in membrane traffic.
In the SK-HEP-1 hepatic adenocarcinoma context, BET1L knockout enables precise dissection of how ER-Golgi trafficking supports malignant phenotypes. Loss of BET1L can impair delivery of matrix metalloproteinases, integrins, and growth factor receptors, potentially attenuating invasive and metastatic capacity. This model also permits investigation of ER stress induction and adaptive responses upon trafficking blockade, offering insights into therapeutic vulnerabilities linked to secretory pathway disruption.
This product is suitable for diverse applications, including monitoring protein expression by western blotting and immunofluorescence, assessing SNARE interactions via co-immunoprecipitation, evaluating vesicular trafficking with VSVG-tsO45 transport assays, measuring transcript levels by RT-qPCR, and testing cell viability. Researchers can further examine secretion dynamics, Golgi enzyme redistribution, and compensatory trafficking mechanisms. For additional technical information and ordering details, please contact Ascent Research.
